The Chairman is under investigation, Wanchen Group: the matters involved are unrelated to the company's Operation | Brief announcement.

① Wancheng Group announces that Chairman Wang Jiankun has been placed under detention and is under investigation; the matters involved are unrelated to the company, and so far the company has not been asked to assist in the investigation. ② Reviewing Wang Jiankun's tenure, during his time, he promoted the transformation of Wancheng Group from edible mushroom cultivation to wholesale snack business.

cls.cnMar 3 10:44 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Suspected of major financial fraud! Orient Group Incorporation is currently at risk of being (Delisted). How can the rights of 0.129 million Shareholders be protected?

① The China Securities Regulatory Commission reported that it has preliminarily determined that the financial information disclosed by Orient Group Incorporation from 2020 to 2023 is severely inaccurate, suspected of significant financial fraud, which may involve serious violations that lead to (Delisted); ② As of the end of the third quarter of 2024, Orient Group Incorporation still has 0.129 million Shareholders, raising concerns about how investors can protect their legal rights.

cls.cnFeb 28 22:01 ET

Haoxiangni faces a difficult profitability dilemma, expecting net income to be in the red for three consecutive years | Interpretations

① Haoxiangni expects a net income loss of between 52 million yuan and 75 million yuan last year, marking the third consecutive year of losses; ② Based on the third-quarter report, the revenue growth of Haoxiangni is accompanied by high sales expenses. ③ With the support of concepts such as 'WeChat Small Shop', Haoxiangni has recently been favored in the secondary market, but the company indicates that the income from this channel is relatively low.

cls.cnJan 23 10:20 ET

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 08:42 ET

Behind the insider trading fine of the chairman of Mogao Co., Ltd.: repeated disclosure errors and persistent Operation pressure | Quick read announcement.

① Mogao Co., Ltd. announced that during the restructuring of Haotian Technology, Chairman Du Guangzhen engaged in insider trading of the company's stocks, making a profit of 0.1994 million yuan. The Qinghai Securities Regulatory Bureau decided to confiscate Du Guangzhen's illegal gains and imposed a fine of 1.5 million yuan; ② The company's operational pressure is "ever-present" — continuous revenue growth without profit, and operating cash flow has been in a net outflow state for five consecutive years.

cls.cnJan 5 20:13 ET